Description
BOTOX 50 Allergan Units is a prescription-only medicine containing botulinum toxin type A, supplied as a powder for solution for injection. Each vial contains 50 Allergan Units of botulinum toxin type A. Following reconstitution, BOTOX acts primarily by inhibiting acetylcholine release from peripheral cholinergic nerve terminals. This temporarily reduces neuromuscular transmission and produces a reversible reduction in targeted muscle activity.
The UK-authorised BOTOX formulation has multiple therapeutic indications, and certain skin and skin-appendage disorders. In aesthetic medicine, the authorised indications include temporary improvement in moderate to severe glabellar lines, lateral canthal lines (crow’s feet), forehead lines and platysma prominence when severity has an important psychological impact in adults.
BOTOX is intended for administration by appropriately qualified healthcare practitioners with expertise relevant to the indication being treated.
Treatment Areas / Indications
The current UK SmPC identifies the following aesthetic indications for BOTOX:
- Glabellar lines between the eyebrows at maximum frown.
- Lateral canthal lines (crow’s feet) at maximum smile.
- Forehead lines at maximum eyebrow elevation.
Usage / Administration
BOTOX 50 Units Dilution
The current UK SmPC provides specific reconstitution options for the 50-Allergan-Unit vial using sterile, unpreserved 0.9% sodium chloride solution for injection.
The required dilution depends on the indication and authorised dosing schedule. The manufacturer specifically warns that the correct diluent volume must be used for the selected vial size to prevent dosing errors.
Ingredient List
- Active ingredient: Botulinum toxin type A — 50 Allergan Units per vial.
BOTOX is supplied as a powder for solution for injection and requires reconstitution before administration.
Presentation & Longevity
BOTOX 50 Allergan Units is supplied as a single vial containing 50 Allergan Units of botulinum toxin type A. It is a powder for solution for injection and is intended for single-patient treatment during a single session.
The unopened product has a stated shelf life of 3 years. Storage requirements should be followed according to the current UK SmPC and product packaging.
Once reconstituted, BOTOX may be stored at 2–8°C for up to 24 hours before use. After this period, used or unused reconstituted product should be discarded. Each vial is for single use only.
For aesthetic facial indications, the duration of clinical effect varies by indication and patient. The UK clinical data report improvement lasting up to approximately 4 months for glabellar lines, while clinical data for forehead and lateral canthal lines show effects that may persist for several months. Individual response varies.
Safety Notes / Contraindications
BOTOX is contraindicated in patients with:
- Known hypersensitivity to botulinum toxin type A or any excipient.
- Infection at the proposed injection site
- but not limited to the above
The product information also includes warnings concerning the potential spread of toxin effects beyond the injection area. Reported complications can include muscle weakness, swallowing or breathing difficulties and other systemic effects.
The MHRA has additionally warned about cases of iatrogenic botulism following therapeutic or cosmetic use of botulinum toxin products and highlights the importance of using authorised products and appropriate professional administration.
BOTOX is not recommended for individuals under 18 years for the aesthetic facial indications covered by the current UK product information.
Regulatory Status
BOTOX 50 Allergan Units is a UK-authorised prescription-only medicine, rather than a CE- or UKCA-marked dermal filler or medical device.
The current UK product information identifies AbbVie Ltd as the Marketing Authorisation Holder and lists UK marketing authorisation PL 41042/0058.
The product’s potency is expressed in Allergan Units. These units are specific to BOTOX and are not interchangeable with units used for other botulinum toxin preparations.
FAQ
1. What is BOTOX 50 Allergan Units?
BOTOX 50 Allergan Units is a prescription-only formulation containing 50 Allergan Units of botulinum toxin type A in a single vial. The active substance temporarily inhibits acetylcholine release at peripheral cholinergic nerve terminals, reducing neuromuscular transmission in the treated area. In UK prescribing information, BOTOX has several therapeutic indications, including specific aesthetic facial-line indications. The product should be prescribed and administered by an appropriately qualified healthcare practitioner with relevant experience.
2. How long does BOTOX 50 units last?
Duration depends on the indication, dose, injection site and individual response. UK clinical data describe improvement in glabellar lines for up to approximately four months. For primary axillary hyperhidrosis treated with 50 Units per axilla, the SmPC reports an effect lasting approximately 4–7 months. These figures should not be interpreted as a guaranteed treatment duration for an individual patient. Repeat treatment must follow the authorised dosing interval for the specific indication.
5. Is BOTOX 50 Allergan Units the same as 50 units of Bocouture?
No. Although BOTOX and Bocouture both contain botulinum toxin type A and have a broadly similar pharmacological mechanism, their potency units are product-specific. The BOTOX UK SmPC expressly states that BOTOX units are not transferable to other botulinum toxin preparations. Therefore, BOTOX 50 Allergan Units should not be considered equivalent to 50 units of Bocouture, Azzalure or another botulinum toxin product. Each medicine must be dosed according to its own authorised information.
